TACROLIMUS (cas 109581-93-3) ointment in the management of atopic keratoconjunctivitis
-
Add time:07/22/2019 Source:sciencedirect.com
SummaryIntroductionAtopic keratoconjunctivitis is frequently associated with atopic eyelid dermatitis. It may require topical steroids, the prolonged use of which may cause ocular complications. TACROLIMUS (cas 109581-93-3) is an immunosuppressant used topically on the skin in atopic dermatitis. The purpose of this study is to evaluate the efficacy and tolerability of tacrolimus 0.1% ointment applied to the eyelids in atopic keratoconjunctivitis.
We also recommend Trading Suppliers and Manufacturers of TACROLIMUS (cas 109581-93-3). Pls Click Website Link as below: cas 109581-93-3 suppliers
Prev:Characterization of O-seryl-N-acetylgalactosaminide glycohydrolase as an α-N-acetylgalactosaminidase
Next:Therapeutic drug monitoring of cyclosporine and TACROLIMUS (cas 109581-93-3) in Myanmar kidney transplant patients) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Comparison of anti-atopic dermatitis activities between DHMEQ and TACROLIMUS (cas 109581-93-3) ointments in mouse model without stratum corneum07/31/2019
- An open-label, randomized trial indicates that everolimus with TACROLIMUS (cas 109581-93-3) or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients07/30/2019
- Relationships between concomitant biologic DMARDs and prednisolone administration and blood TACROLIMUS (cas 109581-93-3) exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients07/29/2019
- Recipient ABCB1, donor and recipient CYP3A5 genotypes influence TACROLIMUS (cas 109581-93-3) pharmacokinetics in liver transplant cases07/28/2019
- Inhibitory effect of immunosuppressive drug TACROLIMUS (cas 109581-93-3) on voltage-gated K+ current in rabbit coronary arterial smooth muscle cells07/27/2019
- Effectiveness and safety of TACROLIMUS (cas 109581-93-3) therapy for myasthenia gravis: A single arm meta-analysis07/26/2019
- Conversion From Immediate-Release TACROLIMUS (cas 109581-93-3) to Prolonged-Release TACROLIMUS (cas 109581-93-3) in Stable Heart Transplant Patients: A Retrospective Study07/25/2019
- A sample processing method for immunoassay of whole blood TACROLIMUS (cas 109581-93-3)07/24/2019
- Therapeutic drug monitoring of cyclosporine and TACROLIMUS (cas 109581-93-3) in Myanmar kidney transplant patients07/23/2019